Regencell Bioscience (NASDAQ:RGC) Hits New 1-Year Low – Here’s What Happened

Shares of Regencell Bioscience Holdings Limited (NASDAQ:RGC) hit a new 52-week low on Thursday . The stock traded as low as $8.55 and last traded at $8.56, with a volume of 470564 shares changing hands. The stock had previously closed at $11.08.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Regencell Bioscience currently has an average rating of “Sell”.

Regencell Bioscience Price Performance

The business’s fifty day simple moving average is $24.06 and its two-hundred day simple moving average is $25.74.

Regencell Bioscience (NASDAQ:RGC) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.00) earnings per share for the quarter.

Hedge Funds Weigh In On Regencell Bioscience

A number of hedge funds have recently bought and sold shares of the business. Squarepoint Ops LLC purchased a new stake in shares of Regencell Bioscience in the second quarter valued at approximately $1,701,000. BNP Paribas Financial Markets acquired a new position in shares of Regencell Bioscience during the 2nd quarter worth approximately $768,000. XTX Topco Ltd purchased a new position in shares of Regencell Bioscience during the 3rd quarter valued at approximately $598,000. Vident Advisory LLC lifted its position in shares of Regencell Bioscience by 65.7% during the 4th quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after buying an additional 11,866 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in Regencell Bioscience by 59,113.8% in the 1st quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after acquiring an additional 17,143 shares during the period. Hedge funds and other institutional investors own 0.13% of the company’s stock.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.